share_log

Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement

Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement

Dermata完成了DMT310痤瘡治療的第三階段科創板-1試驗的招募,預計在2025年3月公佈首要結果,此前成功完成20億的主要終點目標。
Benzinga ·  2024/12/03 22:06

Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement

Dermata完成了DMT310痤瘡治療的第三階段科創板-1試驗的招募,預計在2025年3月公佈首要結果,此前成功完成20億的主要終點目標。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論